SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 17 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
Xeriant Inc. (XERI) Builds Innovation Ecosystem Focused on Advanced Technologies, Commercialization
Xeriant is focused on acquiring, developing and commercializing transformative technologies with applications across multiple industrial…
-
TechForce Robotics Inc. (NGTF): Proving Practical Solutions for the Industry’s Fatigued Areas
Hospitality operators are adopting robotics to target the most physically demanding jobs in hotels, venues,…
-
Drilling Assay Results Boost Deposit Potential, Demonstrates High-Grade Gold Intervals and Continuity for LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF), Setting Stage for Forthcoming PEA
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may…